181 related articles for article (PubMed ID: 36901944)
1. Establishing a Proteomics-Based Signature of AKR1C3-Related Genes for Predicting the Prognosis of Prostate Cancer.
Cui X; Li C; Ding J; Yao Z; Zhao T; Guo J; Wang Y; Li J
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901944
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.
Byrns MC; Mindnich R; Duan L; Penning TM
J Steroid Biochem Mol Biol; 2012 May; 130(1-2):7-15. PubMed ID: 22265960
[TBL] [Abstract][Full Text] [Related]
3. AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling.
Wang B; Gu Y; Hui K; Huang J; Xu S; Wu S; Li L; Fan J; Wang X; Hsieh JT; He D; Wu K
Urol Oncol; 2018 Oct; 36(10):472.e11-472.e20. PubMed ID: 30139661
[TBL] [Abstract][Full Text] [Related]
4. Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.
Neuwirt H; Bouchal J; Kharaishvili G; Ploner C; Jöhrer K; Pitterl F; Weber A; Klocker H; Eder IE
Cell Commun Signal; 2020 Jan; 18(1):11. PubMed ID: 31980029
[TBL] [Abstract][Full Text] [Related]
5. A Mansonone Derivative Coupled with Monoclonal Antibody 4D5-Modified Chitosan Inhibit AKR1C3 to Treat Castration-Resistant Prostate Cancer.
Zhou M; Wang X; Xia J; Cheng Y; Xiao L; Bei Y; Tang J; Huang Y; Xiang Q; Huang S
Int J Nanomedicine; 2020; 15():3087-3098. PubMed ID: 32431503
[TBL] [Abstract][Full Text] [Related]
6. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
[TBL] [Abstract][Full Text] [Related]
7. AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
Zhao J; Zhang M; Liu J; Liu Z; Shen P; Nie L; Guo W; Cai D; Liu J; Armstrong CM; Sun G; Chen J; Zhu S; Dai J; Zhang H; Zhao P; Zhang X; Yin X; Zhu X; Ni Y; Chen N; Zeng H
Prostate; 2019 Sep; 79(13):1553-1562. PubMed ID: 31294486
[TBL] [Abstract][Full Text] [Related]
8. AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression.
Tian Y; Zhao L; Zhang H; Liu X; Zhao L; Zhao X; Li Y; Li J
Diagn Pathol; 2014 Feb; 9():42. PubMed ID: 24571686
[TBL] [Abstract][Full Text] [Related]
9. Transition from androgenic to neurosteroidal action of 5α-androstane-3α, 17β-diol through the type A γ-aminobutyric acid receptor in prostate cancer progression.
Xia D; Lai DV; Wu W; Webb ZD; Yang Q; Zhao L; Yu Z; Thorpe JE; Disch BC; Ihnat MA; Jayaraman M; Dhanasekaran DN; Stratton KL; Cookson MS; Fung KM; Lin HK
J Steroid Biochem Mol Biol; 2018 Apr; 178():89-98. PubMed ID: 29155210
[TBL] [Abstract][Full Text] [Related]
10. Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
Hamid AR; Pfeiffer MJ; Verhaegh GW; Schaafsma E; Brandt A; Sweep FC; Sedelaar JP; Schalken JA
Mol Med; 2013 Jan; 18(1):1449-55. PubMed ID: 23196782
[TBL] [Abstract][Full Text] [Related]
11. Mesoporous silica nanoparticles combined with AKR1C3 siRNA inhibited the growth of castration-resistant prostate cancer by suppressing androgen synthesis in vitro and in vivo.
Chen J; Yang Y; Xu D; Li J; Wu S; Jiang Y; Wang C; Yang Z; Zhao L
Biochem Biophys Res Commun; 2021 Feb; 540():83-89. PubMed ID: 33450484
[TBL] [Abstract][Full Text] [Related]
12. A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics.
Wangtrakuldee P; Adeniji AO; Zang T; Duan L; Khatri B; Twenter BM; Estrada MA; Higgins TF; Winkler JD; Penning TM
J Steroid Biochem Mol Biol; 2019 Sep; 192():105283. PubMed ID: 30641225
[TBL] [Abstract][Full Text] [Related]
13. AKR1C3 mediates pan-AR antagonist resistance in castration-resistant prostate cancer.
Hertzog JR; Zhang Z; Bignan G; Connolly PJ; Heindl JE; Janetopoulos CJ; Rupnow BA; McDevitt TM
Prostate; 2020 Oct; 80(14):1223-1232. PubMed ID: 33258507
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory Interplay of SULT2B1b Sulfotransferase with AKR1C3 Aldo-keto Reductase in Prostate Cancer.
Park S; Song CS; Lin CL; Jiang S; Osmulski PA; Wang CM; Marck BT; Matsumoto AM; Morrissey C; Gaczynska ME; Chen Y; Mostaghel EA; Chatterjee B
Endocrinology; 2020 Feb; 161(2):. PubMed ID: 31894239
[TBL] [Abstract][Full Text] [Related]
15. Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid.
Pippione AC; Carnovale IM; Bonanni D; Sini M; Goyal P; Marini E; Pors K; Adinolfi S; Zonari D; Festuccia C; Wahlgren WY; Friemann R; Bagnati R; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2018 Apr; 150():930-945. PubMed ID: 29602039
[TBL] [Abstract][Full Text] [Related]
16. Consecutive Prostate Cancer Specimens Revealed Increased Aldo⁻Keto Reductase Family 1 Member C3 Expression with Progression to Castration-Resistant Prostate Cancer.
Miyazaki Y; Teramoto Y; Shibuya S; Goto T; Okasho K; Mizuno K; Uegaki M; Yoshikawa T; Akamatsu S; Kobayashi T; Ogawa O; Inoue T
J Clin Med; 2019 May; 8(5):. PubMed ID: 31052459
[TBL] [Abstract][Full Text] [Related]
17. Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.
Dozmorov MG; Azzarello JT; Wren JD; Fung KM; Yang Q; Davis JS; Hurst RE; Culkin DJ; Penning TM; Lin HK
BMC Cancer; 2010 Dec; 10():672. PubMed ID: 21134280
[TBL] [Abstract][Full Text] [Related]
18. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.
Liu C; Lou W; Zhu Y; Yang JC; Nadiminty N; Gaikwad NW; Evans CP; Gao AC
Cancer Res; 2015 Apr; 75(7):1413-22. PubMed ID: 25649766
[TBL] [Abstract][Full Text] [Related]
19. The AKR1C3/AR-V7 complex maintains CRPC tumour growth by repressing B4GALT1 expression.
Wang B; Wu S; Fang Y; Sun G; He D; Hsieh JT; Wang X; Zeng H; Wu K
J Cell Mol Med; 2020 Oct; 24(20):12032-12043. PubMed ID: 32902124
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 regulates androgen synthesis in prostate cancer cells.
Chun JY; Nadiminty N; Dutt S; Lou W; Yang JC; Kung HJ; Evans CP; Gao AC
Clin Cancer Res; 2009 Aug; 15(15):4815-22. PubMed ID: 19638459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
